Real-world 2-year long-term outcomes and prognostic factors in patients receiving nivolumab therapy for recurrent or metastatic squamous cell carcinoma of the head and neck
- 26 February 2022
- journal article
- research article
- Published by Elsevier in Auris Nasus Larynx
- Vol. 49 (5) , 834-844
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Effectiveness and safety of nivolumab in advanced non-small cell lung cancer: The real-life dataLung Cancer, 2018
- Abscopal effect of radiotherapy combined with immune checkpoint inhibitorsJournal of Hematology & Oncology, 2018
- Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expressionOral Oncology, 2018
- Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patientsClinical and Translational Oncology, 2018
- Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non–Small Cell Lung CancerJournal of Thoracic Oncology, 2018
- A randomized, open-label, Phase III clinical trial of nivolumab vs. therapy of investigator’s choice in recurrent squamous cell carcinoma of the head and neck: A subanalysis of Asian patients versus the global population in checkmate 141Oral Oncology, 2017
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2016
- Role of Local Radiation Therapy in Cancer ImmunotherapyJAMA Oncology, 2015
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in miceJournal of Clinical Investigation, 2014
- Investigation of the freely available easy-to-use software ‘EZR’ for medical statisticsBone Marrow Transplantation, 2012